Home » Stocks » Leap Therapeutics

Leap Therapeutics, Inc. (LPTX)

Stock Price: $1.96 USD -0.05 (-2.49%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 109.86M
Revenue (ttm) 375,000
Net Income (ttm) -31.53M
Shares Out 56.05M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $1.96
Previous Close $2.01
Change ($) -0.05
Change (%) -2.49%
Day's Open 2.00
Day's Range 1.93 - 2.03
Day's Volume 479,284
52-Week Range 0.57 - 3.18

More Stats

Market Cap 109.86M
Enterprise Value 83.77M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.05M
Float 21.26M
EPS (basic) -1.57
EPS (diluted) -1.62
FCF / Share -0.76
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.19M
Short Ratio 3.13
Short % of Float 8.32%
Beta 1.95
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 292.95
PB Ratio 6.27
Revenue 375,000
Operating Income -31.04M
Net Income -31.53M
Free Cash Flow -23.95M
Net Cash 26.09M
Net Cash / Share 0.47
Gross Margin n/a
Operating Margin -8,276.53%
Profit Margin -11,093.90%
FCF Margin -6,385.33%
ROA -70.44%
ROE -180.02%
ROIC 679.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 2
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.50*
(180.61% upside)
Low
2.50
Current: 1.96
High
8.00
Target: 5.50
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-33.45-30.75-32.35-27.30-11.92
Net Income-32.90-23.14-29.73-25.63-12.05
Shares Outstanding22.5814.149.169.39-
Earnings Per Share-1.47-2.11-3.31--
Operating Cash Flow-26.90-26.03-22.14-25.34-8.10
Capital Expenditures-0.09--0.06-0.14-
Free Cash Flow-26.99-26.03-22.20-25.48-8.10
Cash & Equivalents4.9917.6625.740.790.41
Total Debt0.55--30.273.14
Net Cash / Debt4.4417.6625.74-29.48-2.74
Assets7.4519.0729.066.461.26
Liabilities9.209.9017.9536.1671.55
Book Value-1.759.1811.12-100-70.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Leap Therapeutics, Inc.
Country United States
Employees 24
CEO Doug E. Onsi

Stock Information

Ticker Symbol LPTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LPTX

Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.